Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive
Her2 Negative Metastatic Breast Cancer
Will patients with HER-2 negative, hormone receptor positive, metastatic breast cancer
who are monitored with serum tumor marker directed disease monitoring (STMDDM) have
non-inferior overall survival compared to patients monitored with usual care?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This randomized research trial studies how well serum tumor marker directed disease
monitoring works in monitoring patients with hormone receptor positive Her2 negative
breast cancer that has spread to other places in the body. Using markers to prompt
when scans should be ordered may be as good as the usual approach to monitoring disease.
Study Reference #: CBRS18109
Lead Researcher (Principal Investigator)
Lead Researcher: Alissa Huston
Study Contact InformationStudy Coordinator: Kathryn Corcoran
Phone: (585) 275-7771
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search